Table 1.118C   Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 or Older; Standard Errors of Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	427	*618*	102	*161*	102	*161*
Zolpidem Products	328	*473*	88	*134*	88	*134*
Eszopiclone Products	101	*134*	9	*19*	9	*19*
Zaleplon Products	82	*72*	12	***	*	***
Benzodiazepine Sedatives	147	*208*	19	*35*	19	*35*
Flurazepam	45	*52*	*	*13*	*	***
Temazepam Products	120	*162*	16	*34*	16	***
Triazolam Products	79	*124*	10	*15*	10	***
Barbiturates	81	*112*	21	*27*	*	***
Any Other Prescription Sedative[1]	228	*367*	48	*80*	48	*81*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.118D   Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 or Older; Standard Errors of Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	0.16	*0.22*	0.04	*0.06*	0.65	*1.01*
Zolpidem Products	0.12	*0.17*	0.03	*0.05*	0.99	*1.60*
Eszopiclone Products	0.04	*0.05*	0.00	*0.01*	0.96	*1.96*
Zaleplon Products	0.03	*0.03*	0.00	*	*	*
Benzodiazepine Sedatives	0.05	*0.08*	0.01	*0.01*	1.11	*2.11*
Flurazepam	0.02	*0.02*	*	*0.00*	*	*
Temazepam Products	0.04	*0.06*	0.01	*0.01*	1.55	*
Triazolam Products	0.03	*0.04*	0.00	*0.01*	1.79	*
Barbiturates	0.03	*0.04*	0.01	*0.01*	*	*
Any Other Prescription Sedative[1]	0.08	*0.13*	0.02	*0.03*	0.87	*1.31*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.119C   Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 to 17; Standard Errors of Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	37	*51*	17	*14*	17	*14*
Zolpidem Products	20	*19*	14	*3*	*	*
Eszopiclone Products	7	*2*	4	*1*	*	*
Zaleplon Products	8	*5*	4	*	*	*
Benzodiazepine Sedatives	13	*10*	5	*5*	*	*
Flurazepam	5	*6*	2	*5*	*	*
Temazepam Products	7	*	2	*	*	*
Triazolam Products	11	*8*	4	*	*	*
Barbiturates	11	*9*	6	*	*	*
Any Other Prescription Sedative[1]	31	*44*	7	*12*	7	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.119D Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 12 to 17; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 12 to 17; Standard Errors of Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	0.15	*0.21*	0.07	*0.06*	2.83	*3.20*
Zolpidem Products	0.08	*0.08*	0.06	*0.01*	*	*
Eszopiclone Products	0.03	*0.01*	0.02	*0.01*	*	*
Zaleplon Products	0.03	*0.02*	0.02	*	*	*
Benzodiazepine Sedatives	0.05	*0.04*	0.02	*0.02*	*	*
Flurazepam	0.02	*0.03*	0.01	*0.02*	*	*
Temazepam Products	0.03	*	0.01	*	*	*
Triazolam Products	0.04	*0.03*	0.02	*	*	*
Barbiturates	0.04	*0.04*	0.02	*	*	*
Any Other Prescription Sedative[1]	0.12	*0.18*	0.03	*0.05*	1.95	*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.120C Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 or Older; Standard Errors of Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	427	*614*	100	*161*	100	*161*
Zolpidem Products	328	*474*	87	*134*	87	*134*
Eszopiclone Products	102	*134*	8	*19*	8	*19*
Zaleplon Products	81	*72*	11	***	*	***
Benzodiazepine Sedatives	147	*208*	18	*35*	18	*35*
Flurazepam	45	*52*	*	***	*	***
Temazepam Products	120	*162*	16	*34*	16	***
Triazolam Products	78	*123*	9	*15*	9	***
Barbiturates	81	*112*	20	*27*	*	***
Any Other Prescription Sedative[1]	225	*362*	46	*79*	46	*80*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

210616

Table 1.120D   Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 or Older; Standard Errors of Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	0.17	*0.24*	0.04	*0.06*	0.66	*1.04*
Zolpidem Products	0.13	*0.19*	0.03	*0.05*	1.00	*1.62*
Eszopiclone Products	0.04	*0.05*	0.00	*0.01*	0.88	*1.96*
Zaleplon Products	0.03	*0.03*	0.00	*	*	*
Benzodiazepine Sedatives	0.06	*0.08*	0.01	*0.01*	1.10	*2.13*
Flurazepam	0.02	*0.02*	*	*	*	*
Temazepam Products	0.05	*0.06*	0.01	*0.01*	1.57	*
Triazolam Products	0.03	*0.05*	0.00	*0.01*	1.74	*
Barbiturates	0.03	*0.04*	0.01	*0.01*	*	*
Any Other Prescription Sedative[1]	0.09	*0.14*	0.02	*0.03*	0.90	*1.37*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.121C Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 to 25; Standard Errors of Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	59	*108*	24	*57*	25	*58*
Zolpidem Products	39	*72*	20	*53*	20	*
Eszopiclone Products	11	*29*	3	*4*	*	*
Zaleplon Products	4	*6*	2	*	*	*
Benzodiazepine Sedatives	19	*37*	11	*12*	*	*
Flurazepam	5	*9*	3	*	*	*
Temazepam Products	11	*12*	9	*9*	*	*
Triazolam Products	18	*34*	7	*7*	*	*
Barbiturates	10	*26*	3	*5*	*	*
Any Other Prescription Sedative[1]	43	*69*	9	*17*	9	*17*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.121D   Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 18 to 25; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 18 to 25; Standard Errors of Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	0.17	*0.32*	0.07	*0.17*	2.12	*4.43*
Zolpidem Products	0.12	*0.21*	0.06	*0.16*	3.93	*
Eszopiclone Products	0.03	*0.09*	0.01	*0.01*	*	*
Zaleplon Products	0.01	*0.02*	0.01	*	*	*
Benzodiazepine Sedatives	0.06	*0.11*	0.03	*0.03*	*	*
Flurazepam	0.02	*0.03*	0.01	*	*	*
Temazepam Products	0.03	*0.03*	0.03	*0.03*	*	*
Triazolam Products	0.05	*0.10*	0.02	*0.02*	*	*
Barbiturates	0.03	*0.08*	0.01	*0.01*	*	*
Any Other Prescription Sedative[1]	0.13	*0.21*	0.03	*0.05*	1.56	*3.27*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

210616

Table 1.122C   Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 26 or Older; Standard Errors of Numbers in Thousands, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	423	*607*	98	*152*	98	*151*
Zolpidem Products	326	*466*	84	*125*	84	*124*
Eszopiclone Products	101	*131*	7	*19*	7	*
Zaleplon Products	81	*71*	11	*	*	*
Benzodiazepine Sedatives	147	*205*	14	*33*	14	*33*
Flurazepam	44	*51*	*	*12*	*	*
Temazepam Products	119	*162*	13	*32*	13	*
Triazolam Products	77	*118*	*	*14*	*	*
Barbiturates	80	*108*	20	*26*	*	*
Any Other Prescription Sedative[1]	220	*356*	45	*78*	45	*78*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.

Table 1.122D   Any Use and Misuse of Prescription Sedative Subtypes in Past Year: Among People Aged 26 or Older; Misuse of Prescription Sedative Subtypes in Past Year: Among Past Year Any Users of Prescription Sedative Subtypes Aged 26 or Older; Standard Errors of Percentages, 2019 and 2020

Sedative Subtype	Any Use in Past Year (2019)	Any Use in Past Year (2020)	Misuse in Past Year among Total Population (2019)	Misuse in Past Year among Total Population (2020)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2019)	Misuse in Past Year among Past Year Any Users of Sedative Subtypes (2020)
ANY PRESCRIPTION SEDATIVE	0.20	*0.28*	0.05	*0.07*	0.69	*1.06*
Zolpidem Products	0.15	*0.21*	0.04	*0.06*	1.01	*1.60*
Eszopiclone Products	0.05	*0.06*	0.00	*0.01*	0.84	*
Zaleplon Products	0.04	*0.03*	0.01	*	*	*
Benzodiazepine Sedatives	0.07	*0.09*	0.01	*0.02*	0.93	*2.20*
Flurazepam	0.02	*0.02*	*	*0.01*	*	*
Temazepam Products	0.05	*0.07*	0.01	*0.01*	1.33	*
Triazolam Products	0.04	*0.05*	*	*0.01*	*	*
Barbiturates	0.04	*0.05*	0.01	*0.01*	*	*
Any Other Prescription Sedative[1]	0.10	*0.16*	0.02	*0.04*	0.99	*1.46*

* = low precision; -- = not available; da = does not apply; nc = not comparable due to methodological changes; nr = not reported due to measurement issues.

NOTE: Estimates in the 2020 column are italicized to indicate caution should be used when comparing estimates between 2020 and prior years because of methodological changes for 2020. Due to these changes, significance testing between 2020 and prior years was not performed. See the *2020 National Survey on Drug Use and Health: Methodological Summary and Definitions* for details.

[1] Includes use or misuse of sedatives containing other active ingredients. Reports of misuse of "any other prescription sedative" that correspond only to the specific sedative categories shown in the table are excluded from estimates for Any Other Prescription Sedative and are included instead in the relevant sedative category.

Definitions: Measures and terms are defined in Appendix A.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2019 and Quarters 1 and 4, 2020.